🔗 Share this article

Given that the United States continues making unprecedented changes to its vaccine guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations during the pandemic and has focused upon potential deaths following COVID-19 vaccination in her recent position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Vaccine Program

Agency leaders planned to reveal sweeping changes to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s immunization schedule, it is understood – a major change that would place the US out of alignment with much of the international standard with little proof for improved outcomes. The announcement has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to head the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a increased emphasis upon reevaluating long-standing immunizations at the FDA.

Høeg has frequently advocated for ending specific childhood immunization guidelines in the US so as to align more similar to Denmark, a nation with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – usually the purview of Dr. Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has little discernible background in pharmaceutical research, approval processes or administrative roles, which has been customary for former heads of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in leading a large organization. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the research of drug development”, commented a former acting FDA commissioner. “Clearly, she lacks the type of experience that former directors who headed CBER have had.”

CDER has an enormous portfolio at the agency, the former commissioner emphasized.

“Everybody just focuses on the novel medication approvals, but the off-patent medication office approves a multitude of generic medications. There’s a biosimilars division, OTC medication office and so forth, and every single one need to be looked after,” she noted. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major administrative component to the job, which manages more than 5,000 staff members. “It is a enormous management job, if you perform it correctly,” the former official concluded.

Official Statement and Disputed Programs

When asked about concerns about Høeg’s qualifications and whether this selection indicates greater collaboration among agency officials on vaccines, a representative stated that the “inquiries are based on flawed premises”.

“Her experience matches the responsibilities of her job,” the representative said, citing the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the commissioner’s new priority voucher program, a contentious expedited therapy clearance system that apparently worried her predecessors. “By what process are these medications being picked for this expedited pathway? Who takes the decisions?” Howard asked. “There’s a lot of lack of transparency occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of most medications, aside from vaccines.”

Public History on Vaccines

With immunizations, Høeg has a more documented, if troubling, past, some experts have noted. She published a research paper using unconfirmed public submissions to assess the incidence of heart inflammation following COVID-19 immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “policy goals” for the current administration encompassed altering regulations for recently developed shots and discontinuing “optional” immunizations, she stated post-election on a online show. At the agency, Høeg has according to sources suggested barring adolescent males from obtaining COVID-19 vaccines.

“She is an thorough ideologue who commences with her preconceived notions and works backwards to accommodate the science in a very disingenuous, dishonest fashion,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined other contrarians, {like|